Background
Our objective was to evaluate the effect of obesity on pre-treatment quality of life (QoL) in gynecologic oncology patients.
Methods
We analyzed collected data from an institution-wide cohort study of women with gynecologic cancers enrolled from 8/2012 to 6/2013. The Functional Assessment of Cancer Therapy-General (FACT-GP), site-specific symptom scales, and the National Institutes of Health Patient Reported Outcomes Measurement Information System (PROMIS©) global mental (GMH) and physical health (GPH) tools were administered. Survey results were linked to clinical data abstracted from medical records (demographics and comorbid conditions). Bivariate tests and multivariate linear regression models were used to evaluate factors associated with QoL scores.
Results
182 women with ovarian, uterine, cervical, and vulvar/vaginal cancers were identified; 152 (82%) were assessed prior to surgery. Mean body mass index (BMI) was 33.5 kg/m2 and race included white (120 [79%]), black (22 [15%]), and other (10 [6.5%]). 98 (64.5%) patients were obese (BMI ≥ 30). On multivariate analysis, subscales for functional (17 vs 19, P=0.04), emotional (16 vs 19, P=0.008), and social (22 vs 24, P=0.02) well-being as well as overall FACT-GP scores (77 vs 86, P=0.002) and PROMIS GPH (45 vs 49, P=0.003) were significantly lower in obese versus non-obese patients.
Conclusions
Prior to cancer treatment, obese gynecologic oncology patients have worse baseline QoL than their normal-weight counterparts. Emerging models of QoL-based cancer outcome measures may disproportionately affect populations with high obesity burden. The potential disparate impact of cancer therapy on longitudinal QoL in the obese vs. non-obese needs to be evaluated.